Overview of Dr. Phillips
Dr. Tycel Phillips is an oncologist in Duarte, CA and is affiliated with City of Hope Comprehensive Cancer Center. He received his medical degree from Rush Medical College of Rush University Medical Center and has been in practice 11 years. He is one of 216 doctors at City of Hope Comprehensive Cancer Center who specialize in Oncology. He has more than 80 publications and over 500 citings.
Office
1500 Duarte Rd
Duarte, CA 91010
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Cook County Health and Hospitals SystemResidency, Internal Medicine, 2006 - 2009
Rush Medical College of Rush University Medical CenterClass of 2006
Certifications & Licensure
CA State Medical License 2022 - 2026
MI State Medical License 2012 - 2025
OH State Medical License 2009 - 2014
IL State Medical License 2006 - 2009- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma Start of enrollment: 2016 May 12
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2018 Dec 24
- Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma Start of enrollment: 2020 Jul 01
Publications & Presentations
PubMed
- 183 citationsRuxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula L. Bockenstedt, Erica L. Campagnaro
The Lancet. Haematology. 2019-09-16 - 33 citationsPembrolizumab in relapsed or refractory Richter syndromePhilippe Armand, Niels Murawski, Daniel Molin, Jasmine Zain, Barbara Eichhorst
British Journal of Haematology. 2020-06-16 - 3 citationsAdding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.Tycel J Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa
Blood Advances. 2023-08-22
Abstracts/Posters
- A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
CAR T Cells and Immunotherapy in Mantle Cell Lymphoma: Bridging Therapy, Toxicities, and Bispecific AntibodiesMarch 30th, 2023- ASH 2022: MCL Trials Break New Ground, May Change PracticeJanuary 30th, 2023
- Mantle Cell Lymphoma at ASH 2022 – More Answers, and More QuestionsDecember 19th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
